Danish pharma innovation: Weight loss trial delivers stunning results

PravdaReport ·
Russia

Phase 2 clinical trials of petrelintide, a long-acting amylin agonist, have demonstrated weight loss of up to 9.8% in patients with obesity who do not have diabetes, according to results published in The Lancet Diabetes & Endocrinology. Developed by the Danish company Zealand Pharma and an international consortium of researchers, petrelintide targets receptors in the brainstem to regulate…

Read original article on PravdaReport →

Related news